Vivos Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$1.18 | -$1.17 | -$1.18 |
| Q2 2024 | 1 | -$1.06 | -$1.04 | -$1.05 |
| Q3 2024 | 1 | -$0.66 | -$0.65 | -$0.66 |
| Q4 2024 | 1 | -$0.49 | -$0.48 | -$0.49 |
| Q1 2025 | 1 | -$0.77 | -$0.77 | -$0.77 |
| Q2 2025 | 1 | -$0.62 | -$0.62 | -$0.62 |
| Q3 2025 | 1 | -$0.58 | -$0.58 | -$0.58 |
| Q4 2025 | 1 | -$0.51 | -$0.51 | -$0.51 |
Vivos Therapeutics, Inc. Earnings Date And Information
Vivos Therapeutics, Inc. last posted its earnings results on Wednesday, August 14th, 2024. The company reported $-0.6 earnings per share for the quarter, topping analysts' consensus estimates of $-1.05 by $0.45. The company had revenue of 3.86 M for the quarter and had revenue of 13.80 M for the year. Vivos Therapeutics, Inc. has generated $-11 earnings per share over the last year ($-11.14 diluted earnings per share) and currently has a price-to-earnings ratio of -1.68. Vivos Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 26th, 2025 based on prior year's report dates.
Vivos Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$0.40 | $4.18 M | $3.86 M | ||
| 08/14/2024 | Q2 2024 | -$1.05 | -$0.60 | 0.45 | $3.60 M | $4.05 M |
| 05/14/2024 | Q1 2024 | -$1.17 | -$1.63 | -0.46 | $3.42 M | |
| 07/29/2024 | Q4 2023 | -$2.32 | $3.25 M | |||
| 09/29/2023 | Q3 2023 | -$1.75 | $4.50 M | $3.30 M | ||
| 08/16/2023 | Q2 2023 | -$3.75 | -$4.62 | -0.87 | $4.12 M | $3.40 M |
| 06/08/2023 | Q1 2023 | $4.82 | $3.86 M | |||
| 03/30/2023 | Q4 2022 | -$5.50 | -$7.93 | -2.43 | $3.95 M | |
| 12/20/2022 | Q3 2022 | -$0.28 | -$6.43 | -6.15 | $3.72 M | $4.25 M |
| 12/20/2022 | Q2 2022 | -$0.28 | -$8.27 | -7.99 | $3.92 M | $4.18 M |
| 11/25/2022 | Q1 2022 | -$4.95 | $3.46 M | |||
| 03/31/2022 | Q4 2021 | -$22.02 | $4.39 M | |||
| 11/15/2021 | Q3 2021 | -$4.00 | -$6.55 | -2.55 | $4.50 M | $4.55 M |
| 08/12/2021 | Q2 2021 | -$4.00 | -$4.87 | -0.87 | $3.60 M | $4.50 M |
| 05/17/2021 | Q1 2021 | -$4.25 | -$4.67 | -0.42 | $3.45 M | |
| 03/25/2021 | Q4 2020 | -$11.32 | $3.31 M | |||
| 09/29/2020 | Q3 2020 | -$3.63 | $3.29 M | |||
| 06/29/2020 | Q2 2020 | -$2.83 | $3.27 M | |||
| 03/31/2020 | Q1 2020 | -$5.17 | $3.20 M | |||
| 12/30/2019 | Q4 2019 | -$5.28 | $3.06 M |
Vivos Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Vivos Therapeutics, Inc.'s earnings date?
Vivos Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 26th, 2025 based off last year's report dates.
-
Did Vivos Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Vivos Therapeutics, Inc. (:VVOS) reported $-0.6 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.05 by $0.45.
-
How can I listen to Vivos Therapeutics, Inc.'s earnings conference call?
The conference call for Vivos Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Vivos Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Vivos Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Vivos Therapeutics, Inc. generate each year?
Vivos Therapeutics, Inc. (:VVOS) has a recorded annual revenue of $13.80 M.
-
How much profit does Vivos Therapeutics, Inc. generate each year?
Vivos Therapeutics, Inc. (:VVOS) has a recorded net income of $13.80 M. Vivos Therapeutics, Inc. has generated $-11.14 earnings per share over the last four quarters.
-
What is Vivos Therapeutics, Inc.'s price-to-earnings ratio?
Vivos Therapeutics, Inc. (:VVOS) has a price-to-earnings ratio of -1.68 and price/earnings-to-growth ratio is -0.08.
